Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Operations and Comprehensive Loss

v3.5.0.2
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Revenues $ 948 $ 1,851
Operating expenses:    
Research and development (related party of $1,036 and $995), net of $65 in grant income 3,156 3,495
General and administrative (related party of $565 and $0) 7,685 5,022
Total operating expenses 10,841 8,517
Operating loss (9,893) (6,666)
Other income (expense):    
Interest expense (related party of $807 and $0) (807) 0
Interest income 22 9
Royalty income 21 32
Total other income (expense) (764) 41
Consolidated net loss (10,657) (6,625)
Net loss attributable to noncontrolling interest 893 0
Net loss attributable to iBio, Inc. (9,764) (6,625)
Comprehensive loss:    
Consolidated net loss (10,657) (6,625)
Other comprehensive loss - foreign currency translation adjustments (4) (25)
Comprehensive loss $ (10,661) $ (6,650)
Loss per common share attributable to iBio, Inc. stockholders - basic and diluted $ (0.12) $ (0.09)
Weighted-average common shares outstanding - basic and diluted 80,973 71,495